Haldol

Haldol is the brand name for the intramuscular injection of haloperidol, a typical antipsychotic of the butyrophenone class. The product is supplied in a sterile solution for intramuscular use, with the exact strength determined by the manufacturer and marketed in the European Union. Haloperidol works as a dopamine D2 receptor antagonist and is prescribed by healthcare professionals for certain psychiatric conditions and symptom management in clinical practice.

Haloperidol injection is indicated for the short‑term management of several acute psychiatric states.

- Acute exacerbations of schizophrenia - Acute psychosis of any etiology - Manic episodes associated with bipolar disorder - Severe agitation requiring rapid control - Pre‑operative sedation in patients at risk of psychotic reactions

Side effects of haloperidol IM vary in frequency and severity.

Common: - Extrapyramidal symptoms such as dystonia, akathisia, or parkinsonism - Sedation or drowsiness - Dry mouth

Serious: - Neuroleptic malignant syndrome - Tardive dyskinesia (persistent involuntary movements) - Cardiac arrhythmias, including QT interval prolongation

When prescribing haloperidol IM, clinicians should evaluate several safety considerations.

- Assess cardiovascular status, especially for QT prolongation risk - Monitor for extrapyramidal symptoms and intervene early - Use cautiously in patients with a history of seizures or other CNS disorders - Avoid in individuals with known hypersensitivity to haloperidol or formulation components - Evaluate hepatic and renal function before initiating therapy - Consider pregnancy, breastfeeding, and elderly patient factors before use

Haloperidol can interact with other medicines that affect the central nervous system or cardiac conduction.

Avoid: - Concurrent use with other dopamine antagonists or strong QT‑prolonging agents (e.g., quinidine, halofantrine) - Monoamine oxidase inhibitors (MAOIs) - High‑dose CNS depressants such as benzodiazepines when rapid sedation is not intended

Use with caution: - Anticholinergic agents that may mask extrapyramidal signs - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which can increase haloperidol levels - CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce efficacy - Lithium, due to potential additive neurotoxic effects - Antihypertensive drugs, as orthostatic hypotension may be enhanced